Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

35.30 -0.05 (-0.16%)
Streaming Delayed Price Updated: 11:43 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
From Vericel Corporation
Via GlobeNewswire
Analyst Ratings for Vericel
 
Via Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
What's Going On With Vericel Shares Trading Higher
Vericel Corp (NASDAQ: VCEL) shares are trading higher by 13.63% to $27.10 Tuesday after the company reported preliminary FY22 revenue results. What Else? 
Via Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
 
Via Benzinga
Looking Into Vericel's Return On Capital Employed
 
Via Benzinga
Vericel: Q2 Earnings Insights
  Vericel (NASDAQ:VCEL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
From Vericel Corporation
Via GlobeNewswire
Vericel: Q1 Earnings Insights
Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
From Vericel Corporation
Via GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Third Quarter 2022 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
From Vericel Corporation
Via GlobeNewswire
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal... 
Via Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
Vericel Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Vericel (NASDAQ:VCEL) reported Q1 sales of $36.07 million. Earnings fell to a loss of $7.09 million, resulting in a 256.4% decrease from last quarter. Vericel earned $4.53 million,... 
Via Benzinga
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga
Vericel Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
Vericel (NASDAQ:VCEL) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Vericel (VCEL) Conference Call Follow this link to access the live... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Lantheus Holdings (NASDAQ:LNTH) stock rose 33.3% to $38.46 during Thursday's regular session. The current volume of 3.4 million shares is 876.7% of Lantheus... 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.